Back
Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.
Journal article

Cell lines expressing recombinant transmembrane domain-activated receptor kinases as tools for drug discovery.

  • Weber H ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Müller D ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Müller M ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Ortiz A ProQinase GmbH, Tumor Biology Center, Freiburg, Germany Department of Cardiology, University of Freiburg, Freiburg, Germany.
  • Birkle M ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Umber S ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Ketterer C ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Siedentopf O ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Feger D ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Totzke F ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Kubbutat M ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Schaechtele C ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Ballmer-Hofer K Paul Scherrer Institute, Biomolecular Research, Villigen, Switzerland.
  • Ehlert JE ProQinase GmbH, Tumor Biology Center, Freiburg, Germany.
  • Graeser R ProQinase GmbH, Tumor Biology Center, Freiburg, Germany (currently) Janssen Pharmaceutical, Beerse, Belgium r.graeser17@gmail.com.
Show more…
  • 2014-09-28
Published in:
  • Journal of biomolecular screening. - 2014
cell-based assays
enzyme assays
enzyme kinetics
oncology
receptor tyrosine kinase
transmembrane domain
Animals
Cell Line
Cell Membrane
Drug Discovery
ErbB Receptors
High-Throughput Screening Assays
Humans
Molecular Targeted Therapy
Mutation
Phosphorylation
Protein Kinase Inhibitors
Protein Structure, Tertiary
Proto-Oncogene Proteins c-kit
Proto-Oncogene Proteins c-met
Rats
Receptor Protein-Tyrosine Kinases
Recombinant Proteins
Transfection
English Many receptor tyrosine kinases (RTKs) represent bona fide drug targets in oncology. Effective compounds are available, but treatment invariably leads to resistance, often due to RTK mutations. The discovery of second-generation inhibitors requires cellular models of resistant RTKs. An approach using artificial transmembrane domains (TMDs) to activate RTKs was explored for the rapid generation of simple, ligand-independent cellular RTK assays, including resistance mutants. The RTKs epidermal growth factor receptor (EGFR), MET, and KIT were chosen in a proof-of-concept study. Their intracellular domains were inserted into a series of expression vectors encoding artificial TMDs, and they were tested for autophosphorylation activity in transient transfection assays. Active constructs could be identified for MET and EGFR, but not for KIT. Rat1 cell pools were generated expressing the MET or EGFR constructs, and their sensitivity to reference tool compounds was compared to that of MKN-45 or A431 cells. A good correlation between natural and recombinant cells led us to build a panel of clinically relevant MET mutant cell pools, based on the wild-type construct, which were then profiled via MET autophosphorylation and soft agar assays. In summary, a platform was established that allows for the rapid generation of cellular models for RTKs and their resistance mutants.
Language
  • English
Open access status
closed
Identifiers
Persistent URL
https://folia.unifr.ch/global/documents/51784
Statistics
Document views: 15 File downloads: